|
|
| (50 dazwischenliegende Versionen von einem Benutzer werden nicht angezeigt) |
| Zeile 1: |
Zeile 1: |
| | __NOTOC__ | | __NOTOC__ |
| | *'''[[Further reading]]''' | | *'''[[Further reading]]''' |
| − | {{tp|p=32251543|t=2020. The COVID-19 (Coronavirus) pandemic: reflections on the roles of librarians and information professionals |pdf=|usr=}}
| |
| − | {{tp|p=32379021|t=2020. Rapid Publication, Knowledge Sharing, and Our Responsibility During the COVID-19 Pandemic |pdf=|usr=}}
| |
| | | | |
| | | | |
| Zeile 8: |
Zeile 6: |
| | | | |
| | *'''[[Reviews on covid19 disease]]''' | | *'''[[Reviews on covid19 disease]]''' |
| − | {{tp|p=32170865|t=ä. Coronavirus disease 2019: What we know?|pdf=|usr=}}
| + | *'''[[Clinical guidelines and advice]]''' |
| − | {{tp|p=32096567|t=ä. Understanding of COVID?19 based on current evidence |pdf=|usr=}}
| + | |
| − | {{tp|p=32249943|t=2020. A comparative-descriptive analysis of clinical characteristics in 2019-coronavirus-infected children and adults |pdf=|usr=}}
| + | |
| | | | |
| | | | |
| − |
| |
| − | *'''[[Clinical guidelines and advice]]'''
| |
| − | {{tp|p=32359076|t=2020. COVID-19: Use of the Clinical Frailty Scale for Critical Care Decisions |pdf=|usr=}}
| |
| − |
| |
| − | {{tp|p=32369222|t=2020. The management of coronavirus disease 2019 (COVID-19) |pdf=|usr=}}
| |
| | | | |
| | *'''[[Respiration mgmt]]''' | | *'''[[Respiration mgmt]]''' |
| − | {{tp|p=32249028|t=2020. The "helmet bundle" in COVID-19 patients undergoing non invasive ventilation |pdf=|usr=}}
| |
| − | {{tp|p=32268933|t=2020. Home PAP devices in COVID-19 infected patients |pdf=|usr=}}
| |
| | | | |
| | + | *'''[[Diagnosis (Laboratory)]]''' |
| | | | |
| | | | |
| − | *'''[[Diagnosis (Laboratory)]]'''
| |
| | *'''[[Diagnosis (Lung CT, Sonography)]]''' | | *'''[[Diagnosis (Lung CT, Sonography)]]''' |
| − | {{tp|p=32280076|t=2020. Clinical and computed tomographic (CT) images characteristics in the patients with COVID-19 infection: What should radiologists need to know?|pdf=|usr=}}
| |
| − |
| |
| | | | |
| | *'''[[Diagnosis (other modalities)]]''' | | *'''[[Diagnosis (other modalities)]]''' |
| | | | |
| | | | |
| − | ----
| |
| | | | |
| | | | |
| | *'''[[Structure of covid19]]''' | | *'''[[Structure of covid19]]''' |
| − | {{tp|p=32238585|t=2020. Isolation and Full-Length Genome Characterization of SARS-CoV-2 from COVID-19 Cases in Northern Italy |pdf=|usr=}}
| |
| − | {{tp|p=32238584|t=2020. Computational inference of selection underlying the evolution of the novel coronavirus, SARS-CoV-2 |pdf=|usr=}}
| |
| | | | |
| | | | |
| | *'''[[Target binding and uptake]]''' | | *'''[[Target binding and uptake]]''' |
| − |
| |
| | *'''[[Cytopathic effects]]''' | | *'''[[Cytopathic effects]]''' |
| − |
| |
| | *'''[[Secretion and shedding]]''' | | *'''[[Secretion and shedding]]''' |
| | | | |
| Zeile 52: |
Zeile 34: |
| | | | |
| | *'''[[Immunology]]''' | | *'''[[Immunology]]''' |
| − |
| |
| | | | |
| | *'''[[Cytokine storm, hemophagocytic lymphohistiocytosis, macrophage activation syndrome]]''' | | *'''[[Cytokine storm, hemophagocytic lymphohistiocytosis, macrophage activation syndrome]]''' |
| − | {{tp|p=32343429|t=2020. Elevated Interleukin-6 and Severe COVID-19: A Meta-Analysis |pdf=|usr=}}
| |
| | | | |
| | | | |
| − | ----
| + | |
| | *'''[[Pathobiology]]''' | | *'''[[Pathobiology]]''' |
| − | {{tp|p=32369204|t=2020. Hepatic involvement in COVID-19 patients: Pathology, pathogenesis, and clinical implications |pdf=|usr=}}
| + | |
| − | {{tp|p=32294295|t=2020. Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19 |pdf=|usr=}}
| + | |
| | | | |
| | *'''[[Disease Models]]''' | | *'''[[Disease Models]]''' |
| | + | |
| | | | |
| | *'''[[Similar diseases and pathomechanisms]]''' | | *'''[[Similar diseases and pathomechanisms]]''' |
| − | {{tp|p=32319148|t=2020. COVID-19: searching for clues among other respiratory viruses |pdf=|usr=}}
| |
| − | {{tp|p=32237148|t=2020. Differences between COVID-19 and suspected then confirmed SARS-CoV-2-negative pneumonia: a retrospective study from a single center |pdf=|usr=}}
| |
| | | | |
| − |
| |
| − | ----
| |
| | | | |
| | | | |
| Zeile 77: |
Zeile 53: |
| | | | |
| | *'''[[Systemic disease, any manifestations]]''' | | *'''[[Systemic disease, any manifestations]]''' |
| | + | |
| | *'''[[Co-Infection]]''' | | *'''[[Co-Infection]]''' |
| | | | |
| − | *'''[[ARDS]]'''
| |
| | | | |
| | *'''[[Pulmonary embolism, coagulation]]''' | | *'''[[Pulmonary embolism, coagulation]]''' |
| | + | |
| | + | |
| | + | |
| | + | |
| | | | |
| | *'''[[Hematology]]''' | | *'''[[Hematology]]''' |
| − | {{tp|p=32344467|t=2020. What do monitoring platelet counts in COVID-19 teach us?|pdf=|usr=}}
| |
| − | {{tp|p=32379934|t=2020. Response to What does monitoring platelet counts in COVID-19 teach us? |pdf=|usr=}}
| |
| − | {{ttp|p=32302435|t=2020. Thrombocytopenia and its association with mortality in patients with COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32278338|t=2020. Exploring possible mechanisms for COVID-19 induced thrombocytopenia: Unanswered questions |pdf=|usr=}}
| |
| | | | |
| | | | |
| | | | |
| | *'''[[Heart]]''' | | *'''[[Heart]]''' |
| − | {{tp|p=32267000|t=2020. Patterns of heart Injury in COVID - 19 and relation to outcome |pdf=|usr=}}
| |
| | | | |
| | | | |
| | | | |
| | *'''[[Neurology, ophthalmology, orl]]''' | | *'''[[Neurology, ophthalmology, orl]]''' |
| | + | |
| | + | |
| | | | |
| | *'''[[Dermatology]]''' | | *'''[[Dermatology]]''' |
| | + | |
| | | | |
| | | | |
| | *'''[[Gastroenterology, hepatology]]''' | | *'''[[Gastroenterology, hepatology]]''' |
| − | {{tp|p=32369204|t=2020. Hepatic involvement in COVID-19 patients: Pathology, pathogenesis, and clinical implications |pdf=|usr=}}
| |
| − | {{tp|p=32343413|t=2020. Letter to the Editor: Lipemic serum in patients with COVID-19 undergoing treatment |pdf=|usr=}}
| |
| − | {{tp|p=32314799|t=2020. Letter to the Editor: Acute hypertriglyceridemia in patients with COVID-19 receiving tocilizumab |pdf=|usr=}}
| |
| | | | |
| | *'''[[Kidney, urology]]''' | | *'''[[Kidney, urology]]''' |
| − | {{tp|p=32249664|t=2020. Focus on the Crosstalk Between COVID-19 and Urogenital Systems |pdf=|usr=}}
| |
| | | | |
| | + | *'''[[The morbid survivor]]''' |
| | | | |
| | *'''[[Risk and special populations]]''' | | *'''[[Risk and special populations]]''' |
| − | *'''[[The morbid survivor]]'''
| + | |
| | + | |
| | + | |
| | *'''[[Case reports]]''' | | *'''[[Case reports]]''' |
| − | {{tp|p=32343395|t=2020. Typically Atypical: COVID-19 Presenting as a Fall in an Older Adult |pdf=|usr=}}
| |
| − | {{tp|p=32227488|t=2020. Diagnosis and treatment of an acute severe pneumonia patient with COVID-19: Case report |pdf=|usr=}}
| |
| − | {{tp|p=32190904|t=2020. Alert for non-respiratory symptoms of Coronavirus Disease 2019 (COVID-19) patients in epidemic period: A case report of familial cluster with three asymptomatic COVID-19 patients |pdf=|usr=}}
| |
| | | | |
| | | | |
| | | | |
| − | *'''[[Case series]]'''
| |
| | | | |
| − | *'''[[Registries]]'''
| |
| | | | |
| | | | |
| − | ----
| |
| | | | |
| | + | *'''[[Case series]]''' |
| | | | |
| − | *'''[[Trials]]'''
| |
| | | | |
| − | *'''[[Candidate Compounds Covid19]]''' | + | *'''[[Registries]]''' |
| − | {{tp|p=32376627|t=2020. Design of potent membrane fusion inhibitors against SARS-CoV-2, an emerging coronavirus with high fusogenic activity |pdf=|usr=}}
| + | |
| | | | |
| | | | |
| | + | *'''[[Trials]]''' |
| | | | |
| − | ----
| + | *'''[[Candidate Compounds Covid19]]''' |
| | | | |
| | | | |
| | *'''[[Other routes of infection]]''' | | *'''[[Other routes of infection]]''' |
| | + | |
| | + | |
| | *'''[[Biophysics of aerosols]]''' | | *'''[[Biophysics of aerosols]]''' |
| | + | |
| | + | |
| | + | |
| | | | |
| | *'''[[Passive protective equipment]]''' | | *'''[[Passive protective equipment]]''' |
| − | {{tp|p=32320083|t=2020. Decontamination of face masks with steam for mask reuse in fighting the pandemic COVID-19: experimental supports |pdf=|usr=}}
| + | |
| | + | |
| | | | |
| | *'''[[Running your hospital]]''' | | *'''[[Running your hospital]]''' |
| | + | |
| | | | |
| | *'''[[Mental aspects of health professionals]]''' | | *'''[[Mental aspects of health professionals]]''' |
| − | {{tp|p=32314806|t=2020. Psychological stress of medical staffs during outbreak of COVID-19 and adjustment strategy |pdf=|usr=}}
| |
| | | | |
| | *'''[[Socio-psychiatric aspects of the status hygienicus]]''' | | *'''[[Socio-psychiatric aspects of the status hygienicus]]''' |
| | + | |
| | + | |
| | | | |
| | | | |
| | *'''[[Avoiding clinical medicine in other diseases]]''' | | *'''[[Avoiding clinical medicine in other diseases]]''' |
| | + | |
| | + | |
| | | | |
| | *'''[[Occupational medicine, workplace security and status hygienicus]]''' | | *'''[[Occupational medicine, workplace security and status hygienicus]]''' |
| | + | |
| | + | |
| | *'''[[Economic aspects of the status hygienicus]]''' | | *'''[[Economic aspects of the status hygienicus]]''' |
| | | | |
| Zeile 162: |
Zeile 145: |
| | | | |
| | *'''[[Host, vector, one health, atmospheric aspects]]''' | | *'''[[Host, vector, one health, atmospheric aspects]]''' |
| − | {{tp|p=32220068|t=ä. Might the many positive COVID19 subjects in Italy have been caused by resident bat?derived zoonotic ??coronaviruses instead of the Wuhan (China) outbreak?|pdf=|usr=}}
| |
| − | {{tp|p=32374472|t=2020. Comments on "Cross-species transmission of the newly identified coronavirus 2019-nCoV" |pdf=|usr=}}
| |
| − | {{tp|p=32346874|t=2020. SARS-CoV-2 and the Hidden Carriers - Sewage, Feline, and Blood Transfusion |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| | | | |
| | *'''[[Origin of Covid19]]''' | | *'''[[Origin of Covid19]]''' |
| | + | |
| | *'''[[Epidemiology]]''' | | *'''[[Epidemiology]]''' |
| | + | |
| | + | |
| | + | |
| | + | |
| | | | |
| | *'''[[Remission, recurrence and persistence]]''' | | *'''[[Remission, recurrence and persistence]]''' |
| | + | |
| | | | |
| | | | |
| Zeile 177: |
Zeile 161: |
| | ---- | | ---- |
| | *'''[[Failure of politics and public health guidance]]''' | | *'''[[Failure of politics and public health guidance]]''' |
| − | {{tp|p=32352911|t=2020. COVID-19 reveals weak health systems by design: Why we must re-make global health in this historic moment |pdf=|usr=}}
| |
| | | | |
| | | | |
| | *'''[[Political abuse of Covid19]]''' | | *'''[[Political abuse of Covid19]]''' |
| − |
| |
| − | *'''[[Lost people]]'''
| |
| − | {{tp|p=32317499|t=2020. A tribute to frontline corona warriors--Doctors who sacrificed their life while saving patients during the ongoing COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32238428|t=2020. Dr Li Wenliang and the Time of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32303602|t=2020. Letter to the Editor: Who was the first doctor to report the Covid-19 outbreak in Wuhan, China?|pdf=|usr=}}
| |
| | | | |
| | | | |
| | | | |
| | + | *'''[[Lost people]]''' |
| | | | |
| | *'''[[Lost civilization]]''' | | *'''[[Lost civilization]]''' |
| | + | |
| | ---- | | ---- |
| | | | |
| | | | |
| | *'''[[History of covid19 exploration]]''' | | *'''[[History of covid19 exploration]]''' |
| − | {{tp|p=32343423|t=2020. A Novel Plan to Deal with SARS-CoV-2 and COVID-19 Disease |pdf=|usr=}}
| + | *'''[[misc.]]''' |
| | | | |
| | | | |
| | + | *'''[[Research tools]]''' |
| | | | |
| | | | |
| − | *'''[[misc.]]'''
| |
| − | {{tp|p=32377057|t=ä. Emerging technologies to combat COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32323591|t=2020. Immunomodulators and immunosuppressants in the era of SARS-CoV-2 - could laboratory tests be the missing link?|pdf=|usr=}}
| |
| − | {{tp|p=32255383|t=2020. Biological treatment use amid the COVID-19 era, a close look at the unresolved perplexity |pdf=|usr=}}
| |
| − | {{tp|p=32301508|t=2020. Assessment of the quality of systematic reviews on COVID-19: A comparative study of previous coronavirus outbreaks |pdf=|usr=}}
| |
| − | {{tp|p=32281667|t=2020. Coronavirus disease 2019: new things to know!|pdf=|usr=}}
| |
| | | | |
| | | | |
| | + | {{tp|p=27490990|t=2017. AVCpred: an integrated web server for prediction and design of antiviral compounds |pdf=|usr=}} |
| | + | {{tp|p=25040500|t=2014. Engineering large viral DNA genomes using the CRISPR?Cas9 system |pdf=|usr=}} |
| | | | |
| − | *'''[[Research tools]]'''
| |
| − | {{tp|p=32339250|t=2020. A potential ex vivo infection model of human induced pluripotent stem cell-3D organoids beyond coronavirus disease 2019 |pdf=|usr=}}
| |
| − | {{tp|p=32275081|t=2020. Evaluate severe acute respiratory syndrome coronavirus 2 infectivity by pseudoviral particles |pdf=|usr=}}
| |
| | | | |
| | *'''[[PrePrint scene]]''' | | *'''[[PrePrint scene]]''' |
| | + | |
| | + | |
| | *'''[[from the ads]]''' | | *'''[[from the ads]]''' |
| | + | |
| | *'''[[Current state of coviki.org]]''' | | *'''[[Current state of coviki.org]]''' |
| | *'''[[on-topic personal thoughts]]''' | | *'''[[on-topic personal thoughts]]''' |
